CN1960781A - 治疗阿尔茨海默氏病的治疗组合 - Google Patents

治疗阿尔茨海默氏病的治疗组合 Download PDF

Info

Publication number
CN1960781A
CN1960781A CNA2005800173902A CN200580017390A CN1960781A CN 1960781 A CN1960781 A CN 1960781A CN A2005800173902 A CNA2005800173902 A CN A2005800173902A CN 200580017390 A CN200580017390 A CN 200580017390A CN 1960781 A CN1960781 A CN 1960781A
Authority
CN
China
Prior art keywords
alzheimer
disease
active
pharmaceutical composition
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800173902A
Other languages
English (en)
Chinese (zh)
Inventor
G·H·拉尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VARNER-LAMBERT Co Ltd
Original Assignee
VARNER-LAMBERT Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VARNER-LAMBERT Co Ltd filed Critical VARNER-LAMBERT Co Ltd
Publication of CN1960781A publication Critical patent/CN1960781A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CNA2005800173902A 2004-04-14 2005-04-04 治疗阿尔茨海默氏病的治疗组合 Pending CN1960781A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56214104P 2004-04-14 2004-04-14
US60/562,141 2004-04-14

Publications (1)

Publication Number Publication Date
CN1960781A true CN1960781A (zh) 2007-05-09

Family

ID=34963723

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800173902A Pending CN1960781A (zh) 2004-04-14 2005-04-04 治疗阿尔茨海默氏病的治疗组合

Country Status (14)

Country Link
EP (1) EP1737539A1 (enExample)
JP (1) JP2007532624A (enExample)
KR (1) KR20060133008A (enExample)
CN (1) CN1960781A (enExample)
AU (1) AU2005232447A1 (enExample)
BR (1) BRPI0509881A (enExample)
CA (1) CA2562069A1 (enExample)
IL (1) IL178120A0 (enExample)
MX (1) MXPA06011969A (enExample)
NO (1) NO20065196L (enExample)
RU (1) RU2006136361A (enExample)
TW (1) TW200533341A (enExample)
WO (1) WO2005099823A1 (enExample)
ZA (1) ZA200608239B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069414A (zh) * 2016-02-11 2018-12-21 西格马瑟拉公司 用于治疗神经退行性疾病的伊格美新

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
WO2020252475A1 (en) * 2019-06-14 2020-12-17 Atiba Joshua O Triple pharmaceutical composition for proteinaceous infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
ATE331523T1 (de) * 2002-04-02 2006-07-15 Janssen Pharmaceutica Nv Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EA012325B1 (ru) * 2002-12-24 2009-08-28 Беллус Хелс (Интернэшнл) Лимитед Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CA2516990A1 (en) * 2003-03-19 2004-09-30 Ares Trading S.A. Treatment of alzheimer's disease
US20050090449A1 (en) * 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069414A (zh) * 2016-02-11 2018-12-21 西格马瑟拉公司 用于治疗神经退行性疾病的伊格美新

Also Published As

Publication number Publication date
NO20065196L (no) 2007-01-03
IL178120A0 (en) 2006-12-31
CA2562069A1 (en) 2005-10-27
AU2005232447A1 (en) 2005-10-27
TW200533341A (en) 2005-10-16
KR20060133008A (ko) 2006-12-22
RU2006136361A (ru) 2008-04-20
JP2007532624A (ja) 2007-11-15
EP1737539A1 (en) 2007-01-03
MXPA06011969A (es) 2006-12-15
ZA200608239B (en) 2008-06-25
WO2005099823A1 (en) 2005-10-27
BRPI0509881A (pt) 2007-10-16

Similar Documents

Publication Publication Date Title
Cummings et al. Alzheimer's disease drug development pipeline: 2020
Cacabelos Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics
Farlow A clinical overview of cholinesterase inhibitors in Alzheimer's disease
Jann et al. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
CN1165310C (zh) 含有(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲基磺酰基)氨基]嘧啶-5基](3r,(5s)-3,5-二羟基庚-6-烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物)
CN1117566C (zh) 包含氨氯地平和抑制素化合物的联合药物形式
TW202139980A (zh) 以大麻二酚及依維莫司(everolimus)治療結節性硬化症之方法
CN1261801A (zh) 报偿缺陷综合征的等位基因多基因诊断和治疗
CN1791408A (zh) 神经系统疾病的治疗
Patterson et al. Niemann-Pick disease, type C and roscoe brady
CN1512887A (zh) 铬/生物素治疗血脂异常和饮食诱发的饭后高血糖症
Caccia Pharmacokinetics and metabolism update for some recent antipsychotics
US20220062296A1 (en) Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment
KR20160147709A (ko) 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법
CN1960781A (zh) 治疗阿尔茨海默氏病的治疗组合
CN1921856A (zh) 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂
CA2417837C (en) Compositions for ameliorating attention-deficient/hyperactivity disorder
WO2017185073A1 (en) Compositions and methods for treating dementia
HK1101036A (en) Therapeutic combination for treatment of alzheimers disease
US9707231B2 (en) Compositions and methods for reduction of amyloid-beta load
CA3217516C (en) NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS WITH A FORM OF PARKINSONISM
Jeong et al. Impact of alcohol use on mortality in the elderly: results from the Korean Longitudinal Study on Health and Aging
CN1814216A (zh) 用于祛斑除痘的中药组合物
US20240122928A1 (en) Methods For Treating Agitation In Subjects With Mild Cognitive Impairment Or Major Neurocognition Disorder
RU2233162C2 (ru) Лекарственные комбинации, включающие (е)-7-[-4-(4-фторфенил)-6-изопропил-2-[-метил(метилсульфонил)амино]- пиримидин-5-ил](3r,5s)-3,5-дигидроксигепт-6-еноевую кислоту и ингибитор, индуктор или субстрат изофермента р450-3а4

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1101036

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1101036

Country of ref document: HK